Inactivation of Myocardin and p16 during Malignant Transformation Contributes to a Differentiation Defect

Cancer Cell

Volumn 11, Issue 2, 2007, Pages 133-146

  Milyavsky, Michael ^a   Shats, Igor ^a   Cholostoy, Alina ^a   Brosh, Ran ^a   Buganim, Yosef ^a   Weisz, Lilach ^a   Kogan, Ira ^a   Cohen, Merav ^a   Shatz, Maria ^a   Madar, Shalom ^a   Kalo, Eyal ^a   Goldfinger, Naomi ^a   Yuan, Jun ^b   Ron, Shulamit ^c   MacKenzie, Karen ^b   Eden, Amir ^c   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CELLCYCLE

Indexed keywords

MYOCARDIN; PROTEIN P16INK4A; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CULTURE MEDIUM; FIBROBLAST; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SERUM; TRANSCRIPTION REGULATION;

EID: 33846804362     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.11.022     Document Type: Article

References (33)

1. Button E., Shapland C., and Lawson D. Actin, its associated proteins and metastasis. Cell Motil. Cytoskeleton 30 (1995) 247-251
2. Chambers R.C., Leoni P., Kaminski N., Laurent G.J., and Heller R.A. Global expression profiling of fibroblast responses to transforming growth factor-β1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am. J. Pathol. 162 (2003) 533-546
3. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
4. Du K.L., Ip H.S., Li J., Chen M., Dandre F., Yu W., Lu M.M., Owens G.K., and Parmacek M.S. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol. Cell. Biol. 23 (2003) 2425-2437
5. Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., and Lassar A.B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267 (1995) 1018-1021
6. Helman L.J., and Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3 (2003) 685-694
7. Horiuchi A., Nikaido T., Taniguchi S., and Fujii S. Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma. J. Natl. Cancer Inst. 91 (1999) 790-796
8. Islam A.H., Ehara T., Kato H., Hayama M., and Nishizawa O. Loss of calponin h1 in renal angiomyolipoma correlates with aggressive clinical behavior. Urology 64 (2004) 468-473
9. Kogan I., Goldfinger N., Milyavsky M., Cohen M., Shats I., Dobler G., Klocker H., Wasylyk B., Voller M., Aalders T., et al. hTERT-immortalized prostate epithelial and stromal-derived cells: An authentic in vitro model for differentiation and carcinogenesis. Cancer Res. 66 (2006) 3531-3540
10. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., and Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413 (2001) 83-86
11. Kumar M.S., and Owens G.K. Combinatorial control of smooth muscle-specific gene expression. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 737-747
12. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PNAS 101 (2004) 811-816 10.1073/pnas.0304146101 Published online January 7, 2004
13. Leavitt J., Gunning P., Kedes L., and Jariwalla R. Smooth muscle alpha-action is a transformation-sensitive marker for mouse NIH 3T3 and Rat-2 cells. Nature 316 (1985) 840-842
14. Li S., Wang D.Z., Wang Z., Richardson J.A., and Olson E.N. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc. Natl. Acad. Sci. USA 100 (2003) 9366-9370
15. Ma Z., Morris S.W., Valentine V., Li M., Herbrick J.A., Cui X., Bouman D., Li Y., Mehta P.K., Nizetic D., et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat. Genet. 28 (2001) 220-221
16. MacKenzie K.L., Franco S., May C., Sadelain M., and Moore M.A. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp. Cell Res. 259 (2000) 336-350
17. Massague J., Blain S.W., and Lo R.S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103 (2000) 295-309
18. Meerson A., Milyavsky M., and Rotter V. p53 mediates density-dependent growth arrest. FEBS Lett. 559 (2004) 152-158
19. Milyavsky M., Shats I., Erez N., Tang X., Senderovich S., Meerson A., Tabach Y., Goldfinger N., Ginsberg D., Harris C.C., et al. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res. 63 (2003) 7147-7157
20. Milyavsky M., Tabach Y., Shats I., Erez N., Cohen Y., Tang X., Kalis M., Kogan I., Buganim Y., Goldfinger N., et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res. 65 (2005) 4530-4543
21. Novitch B.G., Mulligan G.J., Jacks T., and Lassar A.B. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J. Cell Biol. 135 (1996) 441-456
22. Papadimou E., Menard C., Grey C., and Puceat M. Interplay between the retinoblastoma protein and LEK1 specifies stem cells toward the cardiac lineage. EMBO J. 24 (2005) 1750-1761
23. Pipes G.C., Creemers E.E., and Olson E.N. The myocardin family of transcriptional coactivators: Versatile regulators of cell growth, migration, and myogenesis. Genes Dev. 20 (2006) 1545-1556
24. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., and Chinnaiyan A.M. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. USA 101 (2004) 9309-9314
25. Serini G., and Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp. Cell Res. 250 (1999) 273-283
26. Sharpless N.E., Bardeesy N., Lee K.H., Carrasco D., Castrillon D.H., Aguirre A.J., Wu E.A., Horner J.W., and DePinho R.A. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413 (2001) 86-91
27. Taylor L.M., James A., Schuller C.E., Brce J., Lock R.B., and Mackenzie K.L. Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human MRC5 fibroblasts that overcome a telomere-independent crisis during immortalization. J. Biol. Chem. 279 (2004) 43634-43645
28. Thomas D.M., Carty S.A., Piscopo D.M., Lee J.S., Wang W.F., Forrester W.C., and Hinds P.W. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol. Cell 8 (2001) 303-316
29. Wang D., Chang P.S., Wang Z., Sutherland L., Richardson J.A., Small E., Krieg P.A., and Olson E.N. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105 (2001) 851-862
30. Wieser R.J., Faust D., Dietrich C., and Oesch F. p16INK4 mediates contact-inhibition of growth. Oncogene 18 (1999) 277-281
31. Yamamura H., Yoshikawa H., Tatsuta M., Akedo H., and Takahashi K. Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis. Int. J. Cancer 79 (1998) 245-250
32. Zhang H.S., Postigo A.A., and Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ, and contact inhibition. Cell 97 (1999) 53-61
33. Zou T.T., Selaru F.M., Xu Y., Shustova V., Yin J., Mori Y., Shibata D., Sato F., Wang S., Olaru A., et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21 (2002) 4855-4862